REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device ...

California-headquartered Nevro's portfolio includes devices used to manage chronic pain. Credit: Sundry Photography via Shutterstock. · Medical Device Network · Sundry Photography via Shutterstock. US ...

Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., March 7, 2023 /PRNewswire/ -- ...

Nevro Corp. (NYSE: NVRO), a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the ...

Medical device company Nevro has received approval from the US Food and Drug Administration (FDA) and announced a limited market launch of its HFX iQ with HFX AdaptivAI, the AI-driven technology in ...

Furthering Nevro's (NVRO) body of evidence as an innovation leader in pain management, data highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif., Nov. 18, 2024 ...

Please provide your email address to receive an email when new articles are posted on . Delivering HF10 therapy, the Senza II system maintains the performance and durability of the current implantable ...